Jubilant Pharmova jumps after strong management commentary on growth; analysts bullish
Jubilant Pharmova share price: The report, however, said that the company's generic business could face headwinds on steep pricing pressure.
Jubilant Pharmova share price: Shares of Jubilant Pharmova on Wednesday gained more than 5 per cent on the back of a strong commentary from the company's management on growth.
According to a report by domestic brokerage firm Nirmal Bang, the pharmaceutical company expects double-digit growth from FY24. It said that the radiopharma business is back to pre-Covid levels which is a positive. The allergy business is also seeing a double-digit growth with a healthy margin.
The report, however, said that the company's generic business could face headwinds on steep pricing pressure.
Click here to get more updates on Stock Market I Zee Business Live
The pharma company’s management expects double-digit growth in CDMO Sterile Injectables business from FY24, the report said.
Nirmal has maintained Buy rating on the counter with a price target of Rs 432.
During Wednesday's session, the counter an intraday high of Rs 397 on the NSE, zooming more around 5 per cent from previous close of Rs 375.40.
Zee Business panelist and market Ambareesh Balinga said that the momentum in the stock is positive after the management positive commentary. He recommended buying the company's shares for a target of Rs 440/450.
Another panelist Simi Bhaumik said that the stock is taking support at Rs 355-360. The upper-level resistance area is Rs 380-Rs 400. Once it crosses the resistance zone, the stock will show a good move.
Shares of Jubilant Pharmova have yielded a negative return of more than 30 per cent in the past one year.
Also Read: New Year Gift for IDBI Bank customers: Get up to 7.50% interest on FDs - details
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.